CT及MRI对中枢神经系统神经母细胞瘤的诊断价值  

Diagnostic Value of CT and MRI in Neuroblastoma of Central Nervous System

作　　者：于山[1] YU Shan(Department of Imaging,The People's Hospital of Yongcheng,Shangqiu476600,Henan Province,China)

机构地区：[1]河南省商丘市永城市人民医院影像科,河南商丘476600

出　　处：《中国CT和MRI杂志》2018年第10期19-21,共3页Chinese Journal of CT and MRI

摘　　要：目的探讨CT及MRI对中枢神经系统神经母细胞瘤的诊断价值。方法回顾性分析2012年10月-2017年10月我院收治的96例高度怀疑中枢神经系统神经母细胞瘤患儿的临床资料。将行CT检查的42例患儿纳入A组,行MRI检查的54例患儿纳入B组,两组患者均接受手术治疗,并行病理检查。以病理检查结果为"金标准"评价CT及MRI对中枢神经系统神经母细胞瘤的诊断价值,并分析该疾病的CT、MRI影像学特点。结果术后病理检查结果显示:A组患儿中37例被确诊为中枢神经系统神经母细胞瘤,B组患儿中48例被确诊为中枢神经系统神经母细胞瘤。CT诊断中枢神经系统神经母细胞瘤的灵敏度为86.49%(32/37),特异度为80.00%(4/5),准确率为85.71%(3 6/4 2); MRI诊断中枢神经系统神经母细胞瘤的灵敏度为87.50%(42/48),特异度为6 6. 6 7%(4/6),准确率为85.19%(46/54)。结论 CT和MRI对中枢神经系统神经母细胞瘤的诊断准确性均较高,在临床应用价值较高。Objective To explore the diagnostic value of CT and MRI in neuroblastoma of central nervous system.Methods The clinical data of 96 cases of children patients with highly suspected neuroblastoma of central nervous system in our hospital from October 2012 to October 2017 were retrospectively analyzed.42 cases who underwent CT examination were included in the A group,and 54 cases who underwent MRI examination were included in the B group,and the two groups were given surgery and pathological examination.The results of pathological examination were taken as"gold standard"to evaluate the diagnostic value of CT and MRI for neuroblastoma of central nervous system and to analyze the CT and MRI imaging features.Results Postoperative pathological examination showed that 37 cases in the A group were diagnosed with neuroblastoma of central nervous system and 48 cases in the B group.The sensitivity,specificity and accuracy in the diagnosis of neuroblastoma of central nervous system were 86.49%(32/37),80.00%(4/5)and 85.71%(36/42)by CT and were 87.50%(42/48),66.67%(4/6)and 85.19%(46/54)by MRI.Conclusion CT and MRI for neuroblastoma of central nervous system have high diagnostic accuracy and have high value in clinical application.

关 键 词：CT MRI 中枢神经系统 神经母细胞瘤 诊断价值 

分 类 号：R739.41[医药卫生—肿瘤] R445.2[医药卫生—临床医学]